Vical Inc. | Mutual Funds
Mutual Funds that own Vical Inc.
Vanguard Total Stock Market Index Fund
393,089
1.8%
0
0%
07/31/2018
Eventide Healthcare & Life Sciences Fund
300,000
1.38%
-1,400,000
0.06%
06/29/2018
Vanguard Extended Market Index Fund
261,746
1.2%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
105,122
0.48%
0
0%
07/31/2018
Bridgeway Ultra Small Company Fund
87,496
0.4%
0
0.12%
12/31/2017
iShares Micro Cap ETF
54,217
0.25%
0
0.01%
09/06/2018
FCP OP Medical BioHe@lth-Trends
39,000
0.18%
0
0.03%
11/30/2017
Vanguard Institutional Total Stock Market Index Fund
15,634
0.07%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
6,566
0.03%
0
0%
07/31/2018
Pharma/wHealth Fund
6,100
0.03%
0
0.01%
11/30/2017
| Address |
10390 Pacific Center Court
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.vical.com |
| Updated |
07/08/2019 |
| Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. |
